Header Logo

Connection

Donald Jensen to Hepatitis C, Chronic

Back to Details
This is a "connection" page, showing publications Donald Jensen has written about Hepatitis C, Chronic.
Donald Jensen
Connection Strength
8.016
Hepatitis C, Chronic
  1. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther. 2019; 13:2565-2577.
    View in: PubMed
    Score: 0.650
  2. Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver Int. 2016 Apr; 36(4):505-14.
    View in: PubMed
    Score: 0.506
  3. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Liver Int. 2015 Jan; 35 Suppl 1:11-7.
    View in: PubMed
    Score: 0.473
  4. Human immunodeficiency virus and coinfection with hepatitis B and C. Infect Dis Clin North Am. 2014 Sep; 28(3):477-99.
    View in: PubMed
    Score: 0.463
  5. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr; 59(4):1246-9.
    View in: PubMed
    Score: 0.447
  6. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment. J Clin Gastroenterol. 2013 Oct; 47(9):786-93.
    View in: PubMed
    Score: 0.434
  7. The FDA, bridging data, and hepatitis C. Hepatology. 2013 Mar; 57(3):875-7.
    View in: PubMed
    Score: 0.417
  8. Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013 May; 10(5):268-76.
    View in: PubMed
    Score: 0.416
  9. IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? Liver Int. 2012 Feb; 32 Suppl 1:74-8.
    View in: PubMed
    Score: 0.387
  10. A new era of hepatitis C therapy begins. N Engl J Med. 2011 Mar 31; 364(13):1272-4.
    View in: PubMed
    Score: 0.365
  11. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009 Apr 21; 150(8):528-40.
    View in: PubMed
    Score: 0.319
  12. Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure. Liver Int. 2009 Apr; 29(4):481-2.
    View in: PubMed
    Score: 0.318
  13. Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report. Dig Dis Sci. 2009 Jun; 54(6):1369-72.
    View in: PubMed
    Score: 0.305
  14. Hepatitis C: current and future therapies. Mt Sinai J Med. 2008 Aug; 75(4):405-14.
    View in: PubMed
    Score: 0.303
  15. Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol. 2008 Jun; 23(6):844-55.
    View in: PubMed
    Score: 0.300
  16. Future directions in therapy for chronic hepatitis C. Antivir Ther. 2008; 13 Suppl 1:31-6.
    View in: PubMed
    Score: 0.291
  17. Retreatment of chronic hepatitis C in previous non-responders and relapsers. Expert Opin Pharmacother. 2007 Oct; 8(15):2491-503.
    View in: PubMed
    Score: 0.286
  18. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006 May; 43(5):954-60.
    View in: PubMed
    Score: 0.260
  19. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroenterol Hepatol. 2005 Sep; 17(9):899-904.
    View in: PubMed
    Score: 0.248
  20. Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer. BMC Gastroenterol. 2016 Feb 29; 16:30.
    View in: PubMed
    Score: 0.128
  21. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver Int. 2016 07; 36(7):954-62.
    View in: PubMed
    Score: 0.127
  22. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302.
    View in: PubMed
    Score: 0.116
  23. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24; 370(17):1604-14.
    View in: PubMed
    Score: 0.113
  24. Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opin Drug Saf. 2012 Nov; 11(6):901-9.
    View in: PubMed
    Score: 0.101
  25. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol. 2012 Jan-Feb; 11(1):15-31.
    View in: PubMed
    Score: 0.096
  26. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology. 2011 Sep 02; 54(3):789-800.
    View in: PubMed
    Score: 0.093
  27. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol. 2003 Jul; 39(1):106-11.
    View in: PubMed
    Score: 0.053
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.